CRNO-B.ST

Sinker

Cereno Scientific AB (publ) · Healthcare · Sweden · $97M cap · $188K/day traded

SEK 0.1585 +17.1% · close 18 Nov · scored 19 Nov

Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.

6
Score
Get score and insider alerts
Quality
22
Value
36
Momentum
18

As of 19 Nov 2026, the MoatMap Score for Cereno Scientific AB (publ) (CRNO-B.ST) is 6/100, ranked against 25,000+ stocks in 38 markets (Quality 22, Value 36, Momentum 18, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
—
peers 32.6x
ROE
-61.9%
peers 5.7%
D/E
0.8x
peers 0.2x
Dividend %
—
trailing yield

ABOUT CERENO SCIENTIFIC AB (PUBL)

Read

Cereno Scientific AB is a clinical-stage biotechnology company developing innovative disease-modifying therapies for rare cardiovascular diseases, with a primary focus on Pulmonary Arterial Hypertension (PAH). The company's lead drug candidate, CS1, utilizes epigenetic modulation to offer a novel treatment approach, supported by a strategic collaboration with global medical device leader Abbott. Cereno's competitive position is reinforced by a robust patent portfolio and orphan drug designations in major global markets.

FINANCIAL SUMMARY (SEK)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Income and shares
Revenue—————————
Net marginn/mn/mn/mn/m—————
EPS (SEK)-0.09-0.21-0.35-0.38—-0.41-0.44-0.55—
Share count311.4M233.8M281.7M310.5M-0.1%323.1M———
Balance sheet
Debt0.4M45.4M190.4M125.0M578.6%176.0M———
Equity201.5M216.4M191.9M252.6M7.8%————
Debt/equity0.0x0.2x1.0x0.5x+0.5x————
Cash flow
Op. cash flow-18.6M-36.9M-103.4M-111.9M—-71.0M———
Cash flow marginn/mn/mn/mn/m—————
Investing CF-57.5M-49.3M-84.8M-44.3M—————
Financing CF53.6M106.3M228.6M103.3M—————

Cash on hand equals about 7 months of the operating cash used in the last twelve months. Spending on equipment or exploration and any new funding are not counted.

PRICE (1Y) · SEK-95.5%
0.11.12.02.93.88 Oct29 Oct18 Nov
SMA 50SMA 200

Price checkStill fallingExperimental

Made a new 52-week low in the latest session, 98% below its 52-week high. The fall has not stopped yet.

SwingsVery bumpy

Swung more than 97% of stocks we rank over the past year (volatility 115% a year).

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling (this stock): It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor: It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend: None of the above: no recent deep fall and no steady climb.
  • No read yet: Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.

What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.

Calm is not safe: a calm stock can still slide steadily.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
SEK 0.1585
RSI (14)
1.0
52-Week Range-98.2% from high
Low SEK 0.1225High SEK 8.92

SCORE BREAKDOWN

Quality
22
ROIC
-22.4%27.1
ROE
-61.9%14.9
GP/Assets
-0.1%8.4
Op. Margin
26370.2%100.0
FCF/Assets
-48.6%8.3
Piotroski
29.3
Int. Cover
-1.8x31.3
D/E Ratio
0.76x19.2
Current Ratio
0.57x2.7
Value
36
P/E (TTM)
—N/A
EV/EBITDA
-2.6x25.0
P/FCF
—N/A
P/B
0.4x97.2
P/S
-268.9x25.0
Div Yield
—N/A
Momentum
18
52W High %
2%0.2
RS 6M
-100%0.0
SMA 50/200
0.63x6.1
EPS Rev 4W
0.0%46.7
EPS Rev 12W
-2.4%23.3
EPS Improve
+49%54.9
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$97M
P/E (Forward)
-1.3x
Gross Margin
—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRNO-B.ST are excluded.

TickerCompanyMkt CapScore
CRNO-B.STCereno Scientific AB (publ)(you)$97M6
DICOT.STDicot Pharma AB$75M9
CINPHA.STCinclus Pharma Holding AB (publ)$55M7
ORX.STOrexo AB (publ)$55M11
EQL.STEQL Pharma AB (publ)$59M20
MOB.STMoberg Pharma AB (publ)$52M31
NANEXA.STNanexa AB (publ)$205M69
MVIR.STMedivir AB (publ)$94M6
EPIS-B.STEpisurf Medical AB (publ)$100M6
SYNACT.STSynAct Pharma AB$97M10

Peer medians: ROE 5.7% · P/E 32.6x · Gross margin 68.3%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Cereno Scientific AB (publ) (CRNO-B.ST): Stock Score Summary

Cereno Scientific AB (publ) (CRNO-B.ST) has a MoatMap Score of 6/100 based on Quality (22/100), Value (36/100), and Momentum (18/100) factor scores.

Cereno Scientific AB is a clinical-stage biotechnology company developing innovative disease-modifying therapies for rare cardiovascular diseases, with a primary focus on Pulmonary Arterial Hypertension (PAH). The company's lead drug candidate, CS1, utilizes epigenetic modulation to offer a novel treatment approach, supported by a strategic collaboration with global medical device leader Abbott. Cereno's competitive position is reinforced by a robust patent portfolio and orphan drug designations in major global markets.

Director dealings

From 19 Nov 2025 to 19 Nov 2026, MoatMap's records hold no sales and 7 purchases of Cereno Scientific AB (publ) (CRNO-B.ST) shares by its directors. The largest: Sten Sörensen bought 92,592 shares at SEK 5.40 on 2 Jul 2026 (about SEK 500K).

  • 8 Jul 2026: Sten Sörensen bought 48,496 shares at SEK 5.16 (about SEK 250K)
  • 7 Jul 2026: Björn Dahlöf bought 17,813 shares at SEK 5.12 (about SEK 91K)
  • 7 Jul 2026: Jeppe Oevlesen bought 47,459 shares at SEK 5.11 (about SEK 243K)
  • 6 Jul 2026: Sten Sörensen bought 49,455 shares at SEK 5.05 (about SEK 250K)
  • 2 Jul 2026: Björn Dahlöf bought 18,165 shares at SEK 5.49 (about SEK 100K)
CRNO-B.ST insider filings, last 180 days

Key Financial Metrics

PriceSEK 0.1585
Market Cap$97M
P/E (Forward)-1.28
Price/Book0.38
Return on Equity-61.9%
Return on Invested Capital-22.4%
Debt/Equity0.76x
Operating Margin26370.2%
Revenue Growth-54.9%
Free Cash Flow$-19M

Cereno Scientific AB (publ) operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Sweden).

Frequently Asked Questions

What is Cereno Scientific AB (publ)’s (CRNO-B.ST) MoatMap Score?
The MoatMap Score for Cereno Scientific AB (publ) (CRNO-B.ST) is 6/100. It is a composite of Quality (22), Value (36), and Momentum (18), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Cereno Scientific AB (publ) have an economic moat?
Cereno Scientific AB (publ) (CRNO-B.ST) has a Quality factor score of 22/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Cereno Scientific AB (publ) in?
Cereno Scientific AB (publ) (CRNO-B.ST) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Sweden).